Year: 2024
Type: article
Study design: Case Report
Abstract: We present a case of serious and progressive neuropathy shortly following the administration of the herpes zoster subunit (HZ/su) vaccine, otherwise known as Shingrix. The progressive neuropathy occurred a week following the vaccination and progressed until discharge 16 days post-admittance. The patient's mild symptoms persist. The development of neuropathy following HZ/su administration is exceedingly rare, with an attributable risk of three cases per million vaccines administered. A black box warning was issued for this indication, although diagnosis and treatment were not confirmed for this patient. Reporting cases like this is crucial for a comprehensive understanding of vaccine risks and to characterize the underlying etiology of these serious adverse events.
Authors: Michael James Wons, Avani Vaghela, Amna Khalid, Benjamin D. Brooks
Institution: Rocky Vista University
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,591
OpenAlex ID: W4390878038